semaglutide receptor PDB-101: Molecule of the Month: GLP-1 Agonists Semaglutide: A Game-Changer in the

For patients without diabetes using Wegovy for weight management: Routine blood glucose monitoring is not typically required , as hypoglycaemia risk is low Patients should be counselled about maintaining adequate nutritional intake despite appetite suppression Report any symptoms suggestive of hypoglycaemia (tremor, sweating, confusion) to their healthcare provider Annual HbA1c testing may be appropriate for those with prediabetes or metabolic syndrome For patients with type 2 diabetes on combination therapy: Self-monitoring of blood glucose (SMBG) frequency should be individualised based on hypoglycaemia risk Those on insulin or sulphonylureas should monitor more frequently, particularly during Wegovy initiation and dose escalation Continuous glucose monitoring (CGM) may be considered for high-risk individuals or those with impaired awareness, in line with NICE and NHS England access criteria Medication review and adjustment sulphonylurea and insulin doses often require reduction when starting GLP-1 therapy

Bader JL, Li FP, Olmstead PM, et al

Traditional approaches just werent working for me

Investigations include the relationship between IC/BPS, CP/CPPS and other chronic pain conditions (fibromyalgia, chronic fatigue syndrome, and IBS), innovative epidemiological studies, search for clinically important biomarkers, investigation of bacterial, viral and other infectious causative/exacerbating agents, novel brain imaging studies and animal studies to better understand the pathophysiology of these often disabling syndromes